ClinicalTrials.gg
CompletedNCT04199078PALOMA2Updated Sep 2, 2026

Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.

An interventional study of Papilocare vaginal gel in Human Papilloma Virus, Human Papilloma Virus Infection and Cervix Lesion, sponsored by Procare Health Iberia S.L.. Completed at 19 sites in Spain. Open to female participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Procare Health Iberia S.L. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Papillomavirus Infections with a site in Spain — 6 open to participants now, 8 under way, 1 of them phase 3. Papillomavirus Infections · Spain.

Enrollment
9th of 16
164 · median 182
Started
2019
with 2 others
No phase
5 of 21
1 open now
Registered
9th of 21
by date
Lead sponsor
4 of 21
Procare Health Iberia S.L.

Among the 21 studies in Papillomavirus Infections with a site in Spain, this one is the 9th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2019, is one of 5 with no phase, and was the 9th registered.

Papillomavirus Infections

581 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.

Browse Papillomavirus Infections studies →

Open to participants now

6 of the 21 studies in Papillomavirus Infections with a site in Spain are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 89 Papillomavirus Infections studies recruiting now, 40 (45%) set no upper age limit and 44 (49%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 30 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Papillomavirus Infections with a site in Spain, or all of them as a file.
02

Study summary

Phase II, exploratory, randomized, open, controlled and parallel groups clinical trial to evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal mucosa with lesions caused by HPV-HR. All the patients included in the study will be randomized (1:1:1:1) in 4 arms.

Read the detailed description

Phase II, exploratory, randomized, open, controlled and parallel groups clinical trial to evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal mucosa with lesions caused by HPV-HR. All the patients included in the study will be randomized (1:1:1:1) to Arm A (Papilocare schedule A), Arm B (Papilocare schedule B) and Arm C (Papilocare schedule C) Arm D (usual clinical practice-without treatment-).

Selection period of 1 month, followed by randomization and 6 months of treatment followed by a period of another 6 months without treatment.

Patients will visit the site into a total of 5 visits throughout the study. Total study duration: 13 months.

03

Conditions studied

  • Human Papilloma Virus
  • Human Papilloma Virus Infection
  • Cervix Lesion

Keywords

  • HPV
04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Woman between the ages of 30 and 65 (both inclusive).
  2. Able to read and understand the Patient Information Sheet and the form.
  3. Acceptance in the participation of the essay and signature of the Informed Consent form.
  4. ASC-US or LSIL or AG-US cytological result (maximum 3 months prior to inclusion) with concordant colposcopic image (performed at the screening visit).
  5. High risk HPV positive by PCR performed at screening visit.
  6. Is able, at the discretion of the researcher, to comply with the requirements of the trial and without hindrance to follow the instructions and assessments throughout it.

Exclusion criteria

Exclusion Criteria:

  1. immune system alterations, or any other disease or in treatment with .
  2. Non-diagnosed abnormal genital hemorrhage (during the 6 months prior to the screening visit).
  3. To had been vaccinated against HPV.
  4. Other symptomatic vulvovaginal infections.
  5. Surgical cervical excision in the last year or total hysterectomy.
  6. Previous history of gynecological cancer.
  7. Participation in any other clinical trial at present or in the 4 weeks prior to the inclusion of the trial.
  8. Any planned surgery that prevents the correct compliance with the guidelines.
  9. Use of vaginal or other vaginal hormonal treatments.
  10. for the use of Papilocare® gel or known allergies to any of its components.
  11. Women of childbearing age who do not use effective contraceptive methods, pregnant women, with suspicion of pregnancy or woman who are breastfeeding.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
164 participants (actual)

Study arms

  • Experimental
    A - papilocare alternative days treatment

    Arm A: scheme A (21 days / 1 cannula per day + 7 days rest) x 1 month + alternate days up to 6 months (except for menstruation days)

    Device: Papilocare vaginal gel

  • Experimental
    B - papilocare semiintensive treatment

    Arm B: scheme B (21 days / 1 cannula per day + 7 days rest) x 3 months + alternate days up to 6 months (except menstruation days)

    Device: Papilocare vaginal gel

  • Experimental
    C - papilocare intensive treatment

    Arm C: scheme C (21 days / 1 cannula per day + 7 days rest) x 6 months

    Device: Papilocare vaginal gel

  • No intervention
    D - standard of care

    Arm D: usual clinical practice - no treatment

Interventions

  • DevicePapilocare vaginal gel

    Papilocare is a gel vaginally administered by a singledose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution

06

What researchers measure

Primary outcomes

  1. Evaluate the repairment of the cervico-vaginal mucosa with concordant colposcopic image

    Evaluate the repairment of the cervico-vaginal mucosa in positive high risk HPV women with a cytological result of squamous atypia of undetermined significance (ASC-US) or low-grade squamous lesion (LSIL) or glandular atypia of undetermined significance (AG-US), with concordant colposcopic image, 6 months after the start of treatment.

    Time frame: 6 months

Secondary outcomes

  1. Evaluate the repairment of the cervico-vaginal mucosa with concordant colposcopic image

    Evaluate the repairment of the cervico-vaginal mucosa in positive high risk HPV women with a cytological result of squamous atypia of undetermined significance (ASC-US) or low-grade squamous lesion (LSIL) or glandular atypia of undetermined significance (AG-US), with concordant colposcopic image at 3 and 12 months after the start of treatment.

    Time frame: 3 and 12 months

  2. Evaluation of reeptielization degree of the cervico-vaginal mucosa by a likert-type scale

    A likert-type scale will be used to evaluate the reeptielization degree of the cervico-vaginal mucosa at 3, 6 and 12 months after the start of treatment.

    Time frame: 3,6 and 12 months

  3. Presence of HPV at 6 and 12 months after starting treatment.

    Percentage of patients with total and partial clearance of HPV measured by genotyping PCR at 6 and 12 months after starting treatment.

    Time frame: 6 and 12 months]

  4. Evaluation of vaginal health status by vaginal health index score (Bachmann)

    The vaginal health index score (Bachmann) will be used to evaluate vaginal health status at 3, 6 and 12 months from the start of treatment

    Time frame: 3,6 and 12 months]

  5. To evaluate the safety and tolerability of Papilocare® gel during the 6 months of treatment and 6 months of follow-up.

    Safety and tolerability: incidence, nature and severity of adverse events at 6 months of treatment and 6 months of follow-up period.

    Time frame: 6 and 12 months]

  6. To assess the stress received from the patients at 3, 6 and 12 months after starting treatment.

    The stress will be assessed on the PSS14 scale (Perceived Stress Scale 14 items) at 3, 6 and 12 months after the starting treatment.

    Time frame: 3,6 and 12 months]

  7. Evaluation of the satisfaction of papilocare gel use by a likert-type scale

    A likert-type scale will be used to evaluate the satisfaction of papilocare gel use by the patients at 3 and 6 months after the start of treat

    Time frame: 3 and 6 months]

  8. Percentage of patients with good therapeutic compliance

    Percentage of patients with good adherence to the treatment will be used to evaluate the therapeutic compliance at 3 and 6 months after the start of treatment.

    Time frame: 3 and 6 months]

07

Study locations

19 sites
  • Hospital U. de Donostia
    Donostia / San Sebastian, Guipuzcoa 20014, Spain
  • Hospital Universitario HM Puerta del Sur
    Móstoles, Madrid 28938, Spain
  • Hospital Universitari Son Espases
    Palma de Mallorca, Mallorca 07120, Spain
  • Hospital Universitario Nuestra Señora de Candelaria
    Santa Cruz de Tenerife, Tenerife 38010, Spain
  • Hospital General Universitario de Alicante
    Alicante, 03010, Spain
  • Complejo Hospitalario Torrecárdenas
    Almería, 04009, Spain
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Hospital Universitari Vall d' Hebron
    Barcelona, 08035, Spain
  • Hospital de Basurto
    Bilbao, 48013, Spain
  • H. U. Reina Sofía
    Córdoba, 14004, Spain
  • Hospital Universitario Virgen de las Nieves
    Granada, 18014, Spain
  • Assir Hospitalet de Llobregat
    L'Hospitalet de Llobregat, 08904, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital de Manacor
    Manacor, Spain
  • H. R. U. de Málaga / Materno Infantil
    Málaga, 29010, Spain
  • H. General Universitario Santa Lucía
    Murcia, 30202, Spain
  • Hospital Virgen de la Macarena
    Seville, 41009, Spain
  • Hospital Universitari i Politecnic La Fe
    Valencia, 46026, Spain
  • Hospital Álvaro Cunqueiro
    Vigo, 36312, Spain
08

References and documents

Individual participant data

Plan to share: Yes — The PIs from the participant sites gonna received the study protocol and the informed consent form previously to the initiation of the study and every time it occurs an amendment over the protocol, ICF or any other study document. Once the study has finished and the data has been analyzed, the PI's from the sites gonna received the CSR.

Supporting information: Study protocol, Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Jan 2024, 52 months.

Of 119 interventional studies with no phase under Papillomavirus Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's 52 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2019
First posted
Dec 13, 2019
StartActual
Sep 25, 2019
Primary completionActual
Jan 31, 2024
CompletionActual
Jun 30, 2024
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04199078
Lead sponsor
Procare Health Iberia S.L.
Collaborators
Adknoma Health Research
Responsible party
Sponsor
First posted
Dec 13, 2019
Start date
Sep 25, 2019
Primary completion
Jan 31, 2024
Completion
Jun 30, 2024
Last update
Sep 2, 2026

Study contacts

Javier Cortes Bordoy, MD
study chair · AEPCC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion